Inactive Instrument
Taro Pharmaceutical Industries Ltd. Share Price Other OTC
Stocks
IL0010827181
Pharmaceuticals
|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| 01/07 | FDA Grants Tentative Approval for ANDA 212581 Azelaic Acid Topical Foam | CI |
| 25/24/25 | Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
William Coote
DFI | Director of Finance/CFO | 71 | 01/12/2021 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Hagai Reingold
COO | Chief Operating Officer | - | 01/01/2002 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 01/09/2010 | |
James Kedrowski
BRD | Director/Board Member | 74 | 18/05/2011 |
| Chairman | 70 | 23/09/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.33% | -1.12% | +59.27% | +115.42% | 1,05600Cr | |
| -1.06% | -1.65% | +45.77% | +69.98% | 64TCr | |
| -0.65% | -1.36% | +17.22% | +75.49% | 47TCr | |
| -2.66% | -3.71% | +84.92% | +41.15% | 37TCr | |
| -0.06% | -4.12% | +36.31% | +39.39% | 34TCr | |
| -0.79% | +3.01% | +21.11% | +27.79% | 28TCr | |
| -1.19% | -3.09% | +10.75% | +10.61% | 25TCr | |
| -0.50% | +2.75% | +53.85% | +56.84% | 23TCr | |
| -1.47% | -2.37% | +32.35% | +98.89% | 19TCr | |
| Average | -0.88% | +0.12% | +40.17% | +59.51% | 42.4TCr | |
| Weighted average by Cap. | -0.86% | +0.30% | +44.68% | +71.39% |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
